A History of a cGMP Medical Event Investigation

Overview

This book explains the application of the FDA Investigational and New Drug application process, FDA Current Good Manufacturing Practice regulations (cGMP) and Design for Six Sigma (DMADV) in the identification of Customer Requirements, Measurement and Analysis, Design Specifications, and Process Verification and Product Validation.  The Six Sigma methodologies are discussed with examples in preparation of a Project Charter with a supplied format; how to manage and document a team meeting; examples of the ...
See more details below
Other sellers (Paperback)
  • All (9) from $20.70   
  • New (7) from $27.00   
  • Used (2) from $20.70   

Overview

This book explains the application of the FDA Investigational and New Drug application process, FDA Current Good Manufacturing Practice regulations (cGMP) and Design for Six Sigma (DMADV) in the identification of Customer Requirements, Measurement and Analysis, Design Specifications, and Process Verification and Product Validation.  The Six Sigma methodologies are discussed with examples in preparation of a Project Charter with a supplied format; how to manage and document a team meeting; examples of the application of Failure Mode Effect Analysis (FMEA), Quality Functional Deployment (QFD), and the Design Fish-Bone Diagram applied in the design of a coffee cup; an explanation of capability indexes (Cp, Ppk, Cpk) including an example of a Design Of Experiments (DOE) based on improving the capability of a molding operation; and a DMAIC Investigation specific to identifying the cause of failure implicated in the case.
Read More Show Less

Product Details

  • ISBN-13: 9781118396612
  • Publisher: Wiley
  • Publication date: 12/17/2012
  • Edition number: 1
  • Pages: 252
  • Product dimensions: 6.10 (w) x 9.20 (h) x 0.80 (d)

Table of Contents

Part One The Event.

Chapter 1 Francesca

Part Two Drug Discovery five years earlier

Chapter 2 Katlin BioScience - Transgenic Mouse Study

Chapter 3 Oxy-Fox Inhaler

3.1 Kinnen Laboratories.

3.2 Kinnen Laboratories ? Oxy-Fox transfer.

3.3 Due diligence Team - Katlin data Acceptance.

Part Three Kinnen Oxy-Fox Inhaler Market Launch Program

Chapter 4 - Agency IND and NDA Requirements - Six-Sigma Charter - Device Master Record

4.1 Launch Team Meeting number 1

4.2 Meeting with Medical Affairs ? Toxicity Studies

Chapter 5 Meeting Minutes Guidelines.

5.1 Launch Team Meeting number 2

Chapter 6 Project Timing ? Marketing Plan ? Offshore Molding

6.1 Launch Team Meeting Number 3

6.2 Project Financial Review.

6.3 Progress meeting. - Who takes credit for what?

6.4 Morning meeting - Just in Time Manufacturing

Chapter 7 - Process Validation Requirements

7.1 Launch Team Meeting number 4

Chapter 8 - - Failure Mode Effects Analysis

8.1 Launch Team Meeting number 5

Chapter 9 - Design for Manufacturability ? Design for Six Sigma ? Concurrent design.

9.1 Product Development meeting number 1

9.2 Update meeting with Ed Chase and Gordon Taylor

Chapter 10 - Design Fish-Bone Diagram

10.1 Launch Team Meeting number 6

Chapter 11 - Product Specifications

11.1 Product Development meeting number 2

Chapter 12 Design Control.

12.1 Design Team Meeting number 6

12.2 Product Development Staff Meeting

12.3 Engineering one-on-one.

12.4 Program update.

Chapter 13 - Design of Experiments - DOE

13.1 Molding Team Meeting

Chapter 14 Start-up Issues

14.1 Oxy-Fox Inhaler Wrap up and Equipment Start-up

Part four Present day - Funeral

Chapter 15 - Grief

Chapter 16 - The autopsy results

Chapter 17 - The Agency

Part Five - Agency Medical Event letter

Chapter 18 - Kinnen Notification

18.1 Another Agency letter

18.2 Medical Event Review Meeting

Chapter 19 - Investigation Team Management

Chapter 20 - DMAIC Investigation Process - MAIC

Chapter 21 Internal Quality Review

21.1 Meeting with Gail Strom and Marcia Hines

21.2 Executive Management Review

Chapter 22 - The Agency Audit Letter

Chapter 23 - Agency Arrival

Chapter 24 - The Audit

24.1 Agency meeting to review the Qualification documents and first lot to stock quality acceptance records

24.2 Agency meeting to review the Oxy-Fox Inhaler lot used in the NDA Clinical Studies.

24.3 Agency meeting to review the Design and Program team meeting minutes.

24.4 Agency meeting to review the Due-Diligence report, Katlin studies, and Oxy-Fox Design History File.

Chapter 25 - End of day Agency wrap up meeting

Chapter 26 - Kinnen Management Review

Part Six - Reckoning

Chapter 27 - Blame and Responsibility

27.1 The Investigation is a public record.

Chapter 29 Closure

Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star

(0)

4 Star

(0)

3 Star

(0)

2 Star

(0)

1 Star

(0)

Your Rating:

Your Name: Create a Pen Name or

Barnes & Noble.com Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & Noble.com that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & Noble.com does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at BN.com or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation

Reminder:

  • - By submitting a review, you grant to Barnes & Noble.com and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Noble.com Terms of Use.
  • - Barnes & Noble.com reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & Noble.com also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

 
Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)